Edelson Jeff
Johnson & Johnson Pharmaceutical Research and Development.
Healthc Q. 2005;8(3):65-8. doi: 10.12927/hcq.2005.20375.
The novel proposal outlined by Glenn Brimacombe suggests that the federal government directly participate in funding incremental venture capital investment in Canadian biotechnology, with the goal of facilitating commercialization of Canadian biotechnology and health sciences intellectual property. In this way, they suggest, the economic development benefits of the Canadian current investment in health sciences will be increased. The proposal is based on two premises that need further evaluation: (1) the biotechnology sector in Canada presently underperforms in terms of value creation; (2) this underperformance is due to inadequate venture capital investment. It is the author's view that, although several measures do suggest relative system underperformance, this is likely due to structural differences rather than inadequate venture capital investment. The absence of large, integrated, global biopharmaceutical firms based in Canada, the large number of very small biotech firms and the absence of a clear federal policy mandate supporting technology transfer and underinvestment in public sector funded basic research may all be contributory factors. Given the Canadian biotech sector's current efficiency at creating value from limited public investment in basic science, increasing the core CIHR budget might be an even better investment opportunity for limited incremental funding.
格伦·布里马科姆概述的新提议表明，联邦政府应直接参与为加拿大生物技术领域的增量风险资本投资提供资金，目标是推动加拿大生物技术和健康科学知识产权的商业化。他们认为，通过这种方式，加拿大目前在健康科学领域投资所带来的经济发展效益将得到提升。该提议基于两个需要进一步评估的前提：（1）加拿大的生物技术行业目前在价值创造方面表现不佳；（2）这种表现不佳是由于风险资本投资不足。作者认为，尽管有几项措施确实表明该体系相对表现不佳，但这可能是由于结构差异而非风险资本投资不足所致。加拿大缺乏大型、一体化的全球生物制药公司，大量小型生物技术公司的存在，以及缺乏明确支持技术转让的联邦政策指令和公共部门资助的基础研究投资不足，这些都可能是促成因素。鉴于加拿大生物技术行业目前在利用有限的公共基础科学投资创造价值方面的效率，增加加拿大卫生研究院（CIHR）的核心预算对于有限的增量资金而言可能是一个更好的投资机会。
